US9415008 — Dry powder inhaler
Method of Use · Assigned to Teva Branded Pharmaceutical Products R&D Inc · Expires 2034-10-06 · 8y remaining
What this patent protects
This patent protects a dry powder inhaler that delivers a specific combination of fluticasone propionate and salmeterol xinafoate with a lactose carrier.
USPTO Abstract
This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 μg; and wherein the dose provides a baseline-adjusted FEV 1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 μg; and wherein the dose provides a baseline-adjusted FEV 1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-645 |
— | Cutivate |
U-645 |
— | Cutivate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.